Back to top
more

Puma Biotechnology (PBYI)

(Real Time Quote from BATS)

$3.14 USD

3.14
144,911

-0.04 (-1.26%)

Updated Aug 5, 2025 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Vaishali Doshi headshot

Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns

by Vaishali Doshi

INTU, NTGR, PBYI and DASH make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.

Zacks Equity Research

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease

by Zacks Equity Research

BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.

Zacks Equity Research

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

by Zacks Equity Research

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

Zacks Equity Research

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

by Zacks Equity Research

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

Zacks Equity Research

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

by Zacks Equity Research

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

Zacks Equity Research

ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B

by Zacks Equity Research

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

Zacks Equity Research

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

by Zacks Equity Research

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.

Zacks Equity Research

PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal

by Zacks Equity Research

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.

Zacks Equity Research

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

by Zacks Equity Research

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

Zacks Equity Research

Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain

by Zacks Equity Research

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma

by Zacks Equity Research

The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.

Zacks Equity Research

Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane

by Zacks Equity Research

BAYRY files for FDA nod to gadoquatrane, a low-dose MRI contrast agent backed by strong QUANTI study results.

Zacks Equity Research

Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Value Investors Buy Puma Biotechnology (PBYI) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock

by Zacks Equity Research

Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading

Zacks Equity Research

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 400% and 4.65%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y

by Zacks Equity Research

PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.

Zacks Equity Research

JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook

by Zacks Equity Research

Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.